Evidence map›Paper›PMID 41383264›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice.

Hesham Abboud, Brian Steingo, Diana Vargas, Julie Patel, Mary Alissa Willis, Yang Mao-Draayer, Dmitry Khaitov, Jose Avila Ornelas, Adnan Subei, Clifford Reed and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Hesham AbboudMultiple Sclerosis and Neuroimmunology Program, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.ORCID https://orcid.org/0000-0001-5346-8254
Brian SteingoDepartment of Neurology, Infinity Clinical Research, Sunrise, FL, USA.
Diana VargasDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Julie PatelDepartment of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
Mary Alissa WillisThe Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0001-7950-7602
Yang Mao-DraayerDepartment of Neurology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Dmitry KhaitovDepartment of Neurology, Lehigh Valley Health Network, Allentown, PA, USA.
Jose Avila OrnelasPuerto Rico Multiple Sclerosis Center, Caguas, PR, USA.ORCID https://orcid.org/0000-0002-4528-5359
Adnan SubeiNeurology Consultants of Dallas, Dallas, TX, USA.
Clifford ReedDepartment of Neurology, Reading Hospital, West Reading, PA, USA.
William S BaekDepartment of Neurology, Parkside Medical Group, Upland, CA, USA.
Michelle TsaiDepartment of Neurology, Ochsner Health System, New Orleans, LA, USA.
Angie KimDepartment of Neurology, NYU Langone Health and NYU Grossman School of Medicine, New York, NY, USA.
Ahmed Z ObeidatDepartment of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0002-3549-3277
Krupa PandeyDepartment of Neurology, Hackensack University Medical Center, Hackensack Meridian School of Medicine, Hackensack, NJ, USA.
Michael LevyDepartment of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-7969-8346
Negar MolazadehDepartment of Neurology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Robert K ShinDepartments of Neurology and Ophthalmology, University of Virginia, Charlottesville, VA, USA.
Rebecca S RomeroDepartment of Neurology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Paige GouletteDepartment of Neurology, Memorial Healthcare, Owosso, MI, USA.
Rosemarie WalchMemorial Healthcare, Owosso, MI, USA.
Jeanie CotéMemorial Healthcare, Owosso, MI, USA.
Robert PaceDepartment of Neurology, Memorial Healthcare, Owosso, MI, USA.
Buse SengulDepartment of Neurology, Memorial Healthcare, Hollywood, FL, USA.
Benjamin OsborneDepartment of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA.
Ahmad MahadeenDepartment of Neurology, University of Mississippi Medical Center, Jackson, MS, USA.
Lisa FerayorniGenentech, Inc., South San Francisco, CA, USA.
Shervin GholizadehDepartment of Neurology, Genentech, Inc., South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Satralizumab is approved for aquaporin-4 immunoglobulin G-positive (AQP4-IgG Methods: Case information for patients with AQP4-IgG Results: Of 43 patients, 88% were female and 44% self-identified as Black. Median age was 54 (range, 20-82) years, and time since confirmed NMOSD diagnosis was 8 (1-18) years. Reasons for satralizumab initiation included intolerance/safety concerns with existing therapy (30%), new diagnosis (26%), and inadequate disease control (21%). The median duration of satralizumab treatment was 31 (range, 7-104) months, during which three patients (7%) had radiographically confirmed relapses and 15 (35%) experienced a related adverse event. At data cutoff, 35 patients (81%) were receiving satralizumab. Conclusion: Satralizumab was effective and well tolerated in patients with NMOSD, including those who switched from previous treatments due to inadequate disease control and/or intolerance. These real-world outcomes align with long-term safety and efficacy findings from the Phase III SAkura trials.

Indexed as

case studiesmonoclonal antibodiesNeuromyelitis opticasatralizumabtreatment switches

Identifiers

PMID41383264
PMCPMC12690068

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.